Cancer Vaccines Show Promising Results, Offering New Hope for Remission

Experimental cancer vaccines are showing significant promise in treating various forms of cancer, with some patients achieving full remission. These therapeutic vaccines work by stimulating the immune system to recognize and eliminate cancer cells, offering a new avenue of treatment that builds on over a century of research.

One notable case is Molly Hones, who at 31 was diagnosed with stage 4 fibrolamellar carcinoma, a rare liver cancer. After conventional chemotherapy proved ineffective, Hones joined a clinical trial for an experimental cancer vaccine in April 2024. By September, she was in full remission, a state she maintains today. "I think that this is a moment where we really could make cancer curable by using cancer vaccines in addition to other therapies," said Kristen Dahlgren, an external affairs officer at the Parker Institute for Cancer Immunotherapy (PICI). "I think we’re about to change things profoundly for cancer patients."

While the concept of vaccines often brings to mind prevention of infectious diseases, the focus in cancer research is primarily on therapeutic vaccines designed to treat existing cancers. These vaccines aim to create a lasting immune memory, enabling the body to fight off the disease and prevent relapse.

Cancer vaccines can be broadly categorized as either "off-the-shelf" or personalized. Off-the-shelf vaccines target common abnormalities found across many patients with a specific cancer type. Hones's vaccine, for example, was designed to target a particular abnormality common in fibrolamellar carcinoma.

Personalized cancer vaccines, on the other hand, are tailored to an individual's specific tumor. This involves sequencing the DNA of a patient's cancer to identify unique mutations and then developing a custom vaccine to target those specific cancer cells. This process is currently expensive and time-consuming, with researchers working to streamline manufacturing to make personalized vaccines more accessible.

For patients like Ari Nakata, who was diagnosed with metastatic breast cancer after initial treatments failed, clinical trials for cancer vaccines have offered a lifeline. Nakata, who found that standard tumor marker tests did not accurately reflect her cancer's spread, pursued various treatment options and eventually enrolled in a cancer vaccine trial at Washington University, facilitated by PICI. Her treatment required electroporation, a method that uses electrical pulses to enhance vaccine absorption into cells.

Nakata reported positive results, with 24 of her 59 targeted markers responding to the vaccine. "I've got great results from the vaccine, and I have really high hopes about what this can open up," she stated.

Moderna has also announced promising results from Phase 3 trials of its personalized cancer vaccine for melanoma, which could be available as early as next year. This vaccine is also being tested for lung, bladder, kidney, pancreas, and stomach cancers. Cancer vaccines are often used in combination with other therapies, such as immunotherapies that help the immune system detect and attack cancer cells more effectively.

The field is rapidly evolving, with various platforms, including mRNA, DNA, viral vectors, and peptide-based approaches, under development. Researchers are exploring different combinations of vaccines with other treatments to determine optimal strategies for various cancer types. While many of these advanced technologies are still in early stages, the pace of innovation offers significant optimism for the future of cancer treatment.